Scarica l'app Stockscreener
8.05
4.14%
0.32
Dopo l'orario di chiusura:
8.01
-0.04
-0.50%
Precedente Chiudi:
$7.73
Aprire:
$7.85
Volume 24 ore:
1.16M
Relative Volume:
0.84
Capitalizzazione di mercato:
$631.46M
Reddito:
$311.71M
Utile/perdita netta:
$163.05M
Rapporto P/E:
4.0585
EPS:
1.9835
Flusso di cassa netto:
$172.79M
1 W Prestazione:
+7.62%
1M Prestazione:
+13.70%
6M Prestazione:
-25.32%
1 anno Prestazione:
-27.87%
Intervallo 1D:
$7.81
$8.1143
Intervallo di 1 settimana:
$7.51
$8.1143
Portata 52W:
$6.125
$17.43
CorMedix Inc Stock (CRMD) Company Profile
Nome
CorMedix Inc
Settore
Industria
Telefono
908-517-9500
Indirizzo
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Compare CRMD vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
8.05 | 606.36M | 311.71M | 163.05M | 172.79M | 1.9835 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-20 | Aggiornamento | D. Boral Capital | Hold → Buy |
| 2025-06-30 | Downgrade | D. Boral Capital | Buy → Hold |
| 2025-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-07 | Iniziato | Leerink Partners | Outperform |
| 2025-01-13 | Iniziato | D. Boral Capital | Buy |
| 2024-08-26 | Iniziato | Rodman & Renshaw | Buy |
| 2023-08-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-02-17 | Iniziato | Needham | Buy |
| 2020-09-29 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-09-21 | Iniziato | Truist | Buy |
| 2019-12-18 | Iniziato | B. Riley FBR | Buy |
| 2019-03-26 | Reiterato | H.C. Wainwright | Buy |
| 2018-12-06 | Iniziato | ROTH Capital | Buy |
| 2017-09-25 | Reiterato | H.C. Wainwright | Buy |
| 2017-08-10 | Reiterato | Rodman & Renshaw | Buy |
| 2017-05-05 | Reiterato | Rodman & Renshaw | Buy |
| 2016-11-11 | Reiterato | FBR & Co. | Outperform |
| 2016-03-17 | Reiterato | FBR Capital | Outperform |
| 2016-03-03 | Iniziato | FBR Capital | Outperform |
| 2015-11-16 | Reiterato | ROTH Capital | Neutral |
| 2015-10-29 | Reiterato | ROTH Capital | Neutral |
| 2015-05-06 | Downgrade | ROTH Capital | Buy → Neutral |
| 2014-12-08 | Reiterato | ROTH Capital | Buy |
| 2011-10-03 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
CorMedix Inc Borsa (CRMD) Ultime notizie
What CorMedix says before the bell May 14: earnings and update - Stock Titan
CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026 - Yahoo Finance
CorMedix stock falls 5% on fourth quarter earnings miss - Investing.com
Cormedix Stock Pre-Market (+6.2%) : Technical Move Ahead of Key Q2 Catalyst - Trefis
CorMedix reports Q4 revenue of $128.6M, reaffirms 2026 guidance - Investing.com
CorMedix banks on DefenCath sales in Q4 as Melinta adds upside - MSN
CRMD News | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
HC Wainwright & Co. Maintains CorMedix (CRMD) Buy Recommendation - MSN
[ARS] CorMedix Inc. SEC Filing - Stock Titan
CorMedix (CRMD) posts 2025 profit, seeks approval of key charter and governance changes - Stock Titan
CorMedix | 4: Statement of changes in beneficial ownership of securities-Officer Hurlburt Elizabeth - Moomoo
H.C. Wainwright reiterates CorMedix stock rating on trial results By Investing.com - Investing.com India
Truist Financial Maintains CorMedix(CRMD.US) With Buy Rating - Moomoo
CorMedix stock rating maintained at outperform by Citizens By Investing.com - Investing.com India
A Quick Look at Today's Ratings for CorMedix(CRMD.US), With a Forecast Between $13 to $15 - Moomoo
H.C. Wainwright reiterates CorMedix stock rating on trial results - Investing.com UK
H.C. Wainwright Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $13 - Moomoo
RBC Raises Price Target on CorMedix to $14 From $13, Keeps Outperform, Speculative Risk - marketscreener.com
CorMedix stock rating maintained at outperform by Citizens - Investing.com Australia
symbol__ Stock Quote Price and Forecast - CNN
Positive REZZAYO Phase III Prophylaxis Data Might Change The Case For Investing In CorMedix (CRMD) - Sahm
Cormedix Stock Soars Pre-Market After Earnings Beat, Higher Full-Year Guidance - MSN
Needham Maintains CorMedix(CRMD.US) With Buy Rating, Raises Target Price to $15 - Moomoo
CorMedix reports positive Phase III results for rezafungin trial - Investing.com UK
RBC Capital raises CorMedix stock price target on phase III data - Investing.com UK
RBC Capital raises CorMedix stock price target on phase III data By Investing.com - Investing.com South Africa
CorMedix files to sell 6.32M shares of common stock for holders - MSN
CorMedix nears an 11-month low after earnings miss - MSN
CorMedix Eyes $2 Billion Market With Encouraging Data From Fungal Infection Study - Benzinga
CorMedix Announces Positive Phase III Results for Rezafungin in Preventing Invasive Fungal Diseases in Stem Cell Transplant Patients - Minichart
Cormedix Therapeutics announces positive topline results from phase III Respect trial - marketscreener.com
Cormedix Therapeutics Announces Positive Topline Results From Phase Iii Respect Trial - TradingView
CorMedix reports positive Phase III results for rezafungin trial By Investing.com - Investing.com South Africa
Phase III ReSPECT success boosts CorMedix (CRMD) REZZAYO prophylaxis plans - Stock Titan
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients - ChartMill
CorMedix shares slip after unveiling lower revenue outlook for 2026 - MSN
(CRMD) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Do options traders know something about CorMedix stock we don't? - MSN
CRMD Stock Price, Quote & Chart | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
CorMedix Inc Azioni (CRMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.77%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):